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Abstract
Background: We evaluated treatment of osteomyelitis in the foot in the presence of Charcot neuroarthropathy, a
devastating condition with progressive degeneration and joint destruction. We hypothesized that there was a difference
in (1) amputation rate, (2) amputation level, (3) duration of antibiotic therapy, and (4) duration of immobilization
for treatment of osteomyelitis within versus outside the Charcot zone.
Methods: Forty patients (43 ft) diagnosed with Charcot neuroarthropathy and osteomyelitis of the same foot
were retrospectively analyzed. Some patients were successfully treated for osteomyelitis at different sites on
the same foot at different times, thus 60 cases of osteomyelitis were identified in 40 treated patients. Cases
were divided according to osteomyelitis localization: Group 1 had osteomyelitis outside the active Charcot
region; Group 2 had osteomyelitis within the active Charcot region.
Results: Male patients (n = 29; mean age 58.2, range 40.1 to 77.5 years) were younger than female patients
(n = 11; mean age 70.4, range 51.4 to 87.5, p = 0.02 years). Amputation rate was 52% overall (26/40 patients;
26/43 ft): 63% of 30 Group 1 cases and 40% of 30 Group 2 cases (p = 0.09). Amputation level (p = 0.009), duration of
antibiotic treatment (p = 0.045) and duration of immobilization (p = 0.01) differed significantly between the groups.
Conclusions: Osteomyelitis within the Charcot region is associated with a higher level of amputation and longer
durations of antibiotic therapy and immobilization. Osteomyelitis outside and within the Charcot affected region should
be considered separately. If osteomyelitis occurs outside the active Charcot region, primary amputation may be
preferred to internal resection.
Level of Evidence: Retrospective cohort chart review study.
Keywords: Charcot, Osteomyelitis, Amputation, Antibiotic, Treatment
Background
Charcot neuroarthropathy (CN), or diabetic neuropathic
osteoarthropathy with progressive degeneration and
joint destruction as a consequence of any condition
resulting in decreased peripheral sensation [1], is a rare
but devastating complication. The most common cause
of CN is diabetes mellitus; other causes include alcohol-
ism, vitamin B12 or folic acid deficiency, intravenous
drug use, late stage syphilis, syringomyelia, and multiple
sclerosis. While the precise pathogenesis of CN remains
controversial, it is undoubtedly multifactorial [2, 3]. The
current theory of Charcot pathogenesis combines both
neurotraumatic and neurovascular aspects [3–6].
Elements of osteopenia, bone hyperemia, instability,
muscle weakness, and loss of protective sensation place
the limb at risk for developing neuropathic bone and joint
changes [7]. When the compromised foot experiences
trauma and the injury remains unrecognized, the cascade
of events that subsequently ensues will often result in
neuropathic fractures, subluxation or osteoarthropathy
[8], and severe foot deformity. If an ulcer is also present,
and the bone can be palpated through the ulcer, osteo-
myelitis may be an aggravating complication. An infection
can spread into the bone of the foot of a patient with dia-
betes and/or CN from any infection of adjacent soft tissue
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that is complicated by an ulcer [9]. Risk factors for osteo-
myelitis include peripheral neuropathy, vascular disease,
limited joint mobility, foot deformities, abnormal foot
pressures, minor trauma, a history of ulceration or ampu-
tation, and immunosuppression [9–12].
Treatment of early stage CN with the use of crutches
and/or immobilization (i.e., total contact cast and/or
orthosis) may stop the progression of deformity and re-
duce the occurrence of complications [13–16]. However,
if the diagnosis is initially missed, or if treatment is not
initiated, the neuro-osteoarthropathy results in progres-
sive deformities, consecutive ulcers and osteomyelitis,
and is accompanied by a high risk of amputation [17].
Several studies have recently demonstrated that the loca-
tion of diabetic foot ulcers or osteomyelitis affects progno-
sis and healing time [18–24]. However, there is a paucity of
data on healing outcomes of osteomyelitis in the presence
of CN. Dalla Paola et al. [25] evaluated the rate of limb sal-
vage and time to recovery in 33 patients affected by CN
complicated by diffuse osteomyelitis. However, their study
focused on outcomes of surgical treatment to stabilize and
correct bone deformity, rather than on outcomes of treat-
ing the osteomyelitis. The purpose of this study was to
evaluate the treatment of osteomyelitis of the foot in the
presence of CN. We hypothesized that there was a differ-
ence in (1) amputation rate, (2) level of amputation, (3)
duration of antibiotic therapy, and (4) duration of
immobilization after treatment in a CN foot with osteo-
myelitis within versus outside the Charcot zone. The po-
tential effects of the initial surgical treatment, duration of
insulin dependency, and patient compliance with treatment
on these outcomes were also evaluated.
Methods
A retrospective analysis of all medical records of patients
treated for a diagnosis of CN and osteomyelitis of the same
foot between 2002 and 2012 at the outpatient clinic of a
large, urban, orthopedic, university-affiliated research hos-
pital was performed. Inclusion criteria were: a diagnosis of
CN according to the definition and diagnostic criteria of
the French neurologist J.M. Charcot [26], radiographs of
the affected foot, and osteomyelitis of the same side with
radiological findings of osteomyelitis on MRI and/or posi-
tive bone biopsy cultures. Exclusion criteria were: primary
treatment at another institution, or a previous fracture due
to trauma of the same foot. This study was approved by
the Research Ethics Committee of our institution.
Cases were divided into two groups according to
whether the osteomyelitis was localized outside the ac-
tive Charcot region of the foot (Group 1), or within the
active Charcot region of the foot (Group 2). The region
of the foot (i.e., forefoot, midfoot or hindfoot) where the
osteomyelitis was localized was also recorded. To evalu-
ate the effectiveness of the initial surgical treatment, the
surgical management was divided into four categories: 1)
“limited resection” was defined as resection of the in-
fected bone, leaving the surrounding soft tissue in place,
2) “amputation” was defined as surgical removal of part
of the lower limb (bone and soft tissue), 3) “arthrodesis”
was defined as removal of the infected bone combined
with external (Ilizarov fixateur) or internal fixation, and
4) “debridement” was defined as surgical removal of the
infected or necrotic tissue around the wound with
underlying osteomyelitis. Successful treatment was de-
fined as the absence of clinical or radiological signs of a
recurrence of osteomyelitis at the initially affected re-
gion. Duration of treatment was defined as the time
from the first clinic visit to the last clinic visit for a sin-
gle case of osteomyelitis. Antibiotic therapy was discon-
tinued based on the recommendations of in-house
infectious disease specialists, the elimination of clinical
signs of infection (e.g. redness, warmth and swelling), C-
reactive protein level and MRI results. The duration of
antibiotic treatment, duration of immobilization, and
duration of treatment were calculated in days, separately
for each case of osteomyelitis. Other factors likely to in-
fluence outcome were recorded, including duration of
diabetic treatment, insulin dependency, duration of sur-
gery, smoking status, immunosuppressive therapy, per-
ipheral arterial occlusive disease, obesity, age, gender,
incidence of bilateral CN, and patient compliance.
Statistical analysis
Continuous data are reported as means and standard devi-
ations. Categorical data are reported as numbers and per-
centages. Statistical analysis was performed using the
software R (The R Foundation for Statistical Computing,
Version 3.1.0, Vienna, Austria). Differences in categorical
baseline characteristics were evaluated using the Mann-
Whitney U test and the chi-square test. To address cluster-
ing of cases within patients, logistic regression analysis was
performed, with amputation as the dependent variable and
localization of osteomyelitis as the independent variable
with robust standard error (patient identification as a clus-
ter). Duration of antibiotic therapy and duration of
immobilization were analyzed as logarithmic transformed
dependent variables in linear regression with robust stand-
ard error (patient identification as a cluster). Categorical
data (i.e., amputation level) were assessed using Fisher’s
exact test. The significance level was set at p < 0.05. For
graphical visualization, Tukey boxplots were depicted with
whiskers maximum of 1.5 interquartile ranges (IQR).
Results
Study population
This retrospective chart review identified 70 patients di-
agnosed with CN and osteomyelitis of the same foot be-
tween 2002 and 2012. Thirty patients were excluded
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from the study due to incomplete medical reports (n =
26) or absence of reliable evidence of osteomyelitis (n =
4). Three patients (#7, #26, and #34) had bilateral osteo-
myelitis combined with CN. Thus, 40 patients (43 ft)
were included in the study (Table 1).
Due to the progressive nature of CN, some patients
were successfully treated for multiple episodes of osteo-
myelitis, which occurred independently of each other, at
different sites on the same foot, or at different time
points, months or years apart. One patient (#22) pre-
sented with osteomyelitis within the Charcot region, and
then one month later presented with a separate case of
osteomyelitis outside the Charcot region. Ten patients
(#1, #4, #7 right foot, #11, #18, #25, #26 left foot, #27,
#28, #39) had 2 separately treated and resolved cases of
osteomyelitis on the same foot, months apart. Three pa-
tients (#6, #7 left foot, #21) had 3 separately treated and
resolved cases of osteomyelitis on the same foot, months
apart. The mean duration between independent cases of
osteomyelitis in a single patient, measured as the date
treatment ended for the first case to the date of diag-
nosis of the second case, was 16.3 months (range: 2.4
to 33.5 months).Thus, in total, we identified 60 cases
of osteomyelitis for the 40 patients included in this
study. The 60 cases were divided into two groups ac-
cording to the localization of the osteomyelitis and
CN, with 30 cases in Group 1 (i.e., osteomyelitis out-
side the active Charcot region), and 30 cases in
Group 2 (i.e., osteomyelitis within the active Charcot
region of the foot).
Patient demographic characteristics and individual
treatments are summarized in Table 1. There were 29
(73%) male and 11 female patients; 44/60 (73%) cases of
osteomyelitis were in male patients. Mean age was 61.6
± 12.4 (range, 40.1 to 87.5) years. Male patients (mean
age 58.2 ± 10.5; range, 40.1 to 77.5 years) were significantly
younger than female patients (mean age 70.4 ± 13.4; range
51.4 to 87.5 years; p = 0.02). Twenty-three (58%) patients
were between 50 and 70 years of age at initial diagnosis of
CN; 8 (20%) were over 70 years of age, and 9 (23%) were
under 50 years of age. No female patient was under
50 years of age at initial diagnosis of CN.
Twenty-five of 40 (63%) patients had insulin-
dependent diabetes and 15 had non-insulin-dependent
diabetes. The mean duration of treatment for diabetes at
the time of initial treatment for osteomyelitis was 17.7 ±
13.2 (range: 0.2 to 52.9) years. The mean duration of
treatment for diabetes at the time of initial diagnosis of
CN was 15.5 ± 13.8 (range: 0.6 to 52.9) years. In Group
1, 16/30 (53%) cases were insulin-dependent; in Group
2, 19/30 (63%) cases were insulin-dependent.
There was no significant difference in age, gender, and
duration of treatment for diabetes between the groups
(p = 0.81, p = 0.82, and p = 0.30, respectively) (Table 2).
Amputation rate
An amputation was performed in 31/60 (52%) cases of
osteomyelitis (26/40 patients; 26/43 ft). In the 44 male
cases, 21 (48%) amputations were performed. In the 16
female cases, 10 (63%) amputations were performed.
The amputation rate was similar for Group 1 with
osteomyelitis outside the Charcot region (19 amputa-
tions; 63%) and Group 2 with osteomyelitis within the
Charcot region (12 amputations; 40%) (p = 0.09). Ampu-
tation rate did not differ significantly based on insulin
dependency or compliance with treatment.
Level of amputation
The 31 amputations included 16 toe, 4 transmetatarsal, 1
Lisfranc, 1 Chopart, 8 transtibial and 1 transfemoral am-
putation. A major amputation (i.e., above the level of the
ankle) was performed in 3/30 (10%) cases in Group 1 with
osteomyelitis outside the active Charcot region and 6/30
(20%) cases in Group 2 with osteomyelitis within the ac-
tive Charcot region (p = 0.009) (Fig. 1). The level of ampu-
tation did not differ significantly based on insulin
dependency or compliance with treatment (Fig. 2).
Duration of antibiotic treatment
The duration of antibiotic treatment was significantly
shorter in Group 1 (mean 55.7 ± 48.9, range: 9 to 228 days)
compared to Group 2 (mean 84.1 ± 51.2, range: 6 to
238 days, p = 0.045). Within Group 1, the mean duration
of antibiotic treatment was 43.9 days shorter in cases ini-
tially treated with amputation compared to cases initially
treated with internal resection (p = 0.02). Within Group 2,
Fig. 1 Histogram showing the level of amputation in Group 1 with
osteomyelitis outside the Charcot region (n = 30) and in Group 2
with osteomyelitis within the Charcot region (n = 30) when
treatment was successfully completed, and in the absence of
recurrence of osteomyelitis
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the duration of antibiotic treatment was similar across all
initial surgical treatments (p = 0.09) (Fig. 3).
Duration of immobilization
The duration of immobilization was 61.4 days shorter in
Group 1 where osteomyelitis outside the active Charcot
region (mean 83.1 ± 70.5, range 19 to 304 days), compared
to Group 2 with osteomyelitis within the active Charcot
region (mean 144 ± 91.8, range 17 to 389 days, p = 0.01).
There was no significant difference in the duration of
immobilization between the different initial surgical treat-
ments within each group (p = 0.40 and p = 0.90, respect-
ively) (Fig. 4).
Discussion
Treatment of CN complicated by osteomyelitis is a com-
plex, long-lasting procedure, demanding considerable
perseverance from patients and physicians. Multiple surgi-
cal procedures, including a high rate of amputations, as
well as prolonged antibiotic therapy and immobilization
are often required [27]. This study demonstrated that pa-
tients treated for osteomyelitis within the Charcot region
on the foot underwent more high level amputations and
had longer durations of antibiotic treatment and
immobilization than patients treated for osteomyelitis out-
side the Charcot region. However, the amputation rate
was statistically similar for both groups.
Amputation was required during the course of treat-
ment in 31/60 cases treated for CN and osteomyelitis of
the same foot, whereas 29/60 cases were successfully
treated with a combination of conservative surgery and
antibiotic medication. The overall amputation rate did
not differ significantly between the patients treated for
osteomyelitis outside the Charcot region and those
Fig. 2 Histograms showing the level of amputation in relation to (a) insulin dependency (n = 35 insulin-dependent diabetes, n = 25 non-insulin-
dependent diabetes) and (b) compliance with treatment for osteomyelitis and Charcot arthropathy (n = 23 compliant, n = 27 non-compliant, n =
10 not recorded)
Fig. 3 The duration of antibiotic therapy in Group 1 with osteomyelitis outside the Charcot region (mean 55.7 ± 48.9 days) and in Group 2 with
osteomyelitis inside the Charcot region (mean 84.1 ± 51.2 days) differed significantly (p = 0.045). In Group 1, the duration of antibiotic therapy was
43.9 days shorter in cases of initial amputation compared to cases of initial internal resection (p = 0.02). In Group 2, the duration of antibiotic therapy
was similar for the different initial surgical treatments (p = 0.09). Asterisk = significant difference
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treated for osteomyelitis within the Charcot region.
Wukich et al. [28] recently reported 16 of 43 patients
(37.2%) with CN hospitalized for osteomyelitis under-
went major amputation, but this rate can be expected to
be lower in less severe cases that can be effectively man-
aged in an outpatient setting such as ours. When consid-
ering the level of amputation, the 20% rate of major
amputations we reported in cases of osteomyelitis within
the Charcot region is comparable to the 23% rate of
major amputations reported by Gazis et al. [29] in 47 pa-
tients with CN managed by a specialist diabetic foot
clinic. However, our 10% amputation rate in cases of
osteomyelitis outside the active Charcot region was sig-
nificantly lower.
The mean duration of antibiotic treatment in this
study ranged from 56 to 84 days, where patients with
osteomyelitis within the active Charcot region required a
longer duration of treatment. Two recent studies re-
ported similar mean durations of antibiotic treatment of
76 days [30] and 77 days [31] for the nonsurgical man-
agement of diabetic foot osteomyelitis. Mutluoglu et al.
[32] reported a mean of 47 days of antibiotic treatment
in 37 patients with diabetic foot osteomyelitis, of whom
22 underwent minor amputation. In 2008, the Inter-
national Working Group on the Diabetic Foot deter-
mined that there are no data to inform the optimal
duration of antibiotic therapy [4].
In this study, the mean duration of immobilization
ranged from 83 to 144 days, with patients with osteo-
myelitis within the active Charcot region requiring a lon-
ger period of immobilization. Several clinical trials
evaluated different off-loading techniques for the treat-
ment of diabetic foot ulcers and reported the duration of
immobilization with a total contact cast ranged from 35
to 69 days [33–36]. However, these trials excluded pa-
tients with osteomyelitis. In a study of 288 patients with
acute Charcot foot that included 81 cases of ulceration
and 20 cases of osteomyelitis, the median duration of
immobilization for resolution of symptoms was 273 days
[37]. Literature reporting specifically on immobilization
of the Charcot foot with osteomyelitis is notably lacking.
The region of the foot on which the osteomyelitis was
located likely contributed to the significant differences in
the amputation level (p < 0.001), duration of antibiotic
treatment (p = 0.045), and duration of immobilization (p
= 0.01) observed between the groups who presented with
osteomyelitis within the Charcot region versus outside the
Charcot region. In the group with osteomyelitis within the
Charcot region, a major amputation was performed in 3/8
cases with osteomyelitis in the hindfoot, 3/13 cases with
osteomyelitis in the midfoot, and none of the cases with
osteomyelitis in the forefoot. In the group with osteomye-
litis outside the Charcot region, the osteomyelitis was al-
most exclusively (29/30 cases) located in the forefoot, thus
elimination of infection by internal resection or amputa-
tion could be achieved more reliably. Diabetic foot ulcers
and osteomyelitis located in the forefoot have been dem-
onstrated to have a shorter healing time compared to
those in the hindfoot [18, 20–22, 24]. We therefore rec-
ommend that patients with osteomyelitis of the foot
within versus outside the Charcot region should be ana-
lyzed separately in future research evaluating the outcome
and treatment of CN and osteomyelitis.
The initial surgical treatment provided in this study
did not affect the duration of antibiotic therapy or
immobilization in the group with osteomyelitis in the
Charcot region, but this may be due to the small sample
sizes for each type of surgery. In the group with osteo-
myelitis outside the Charcot region, the duration of anti-
biotic therapy was 6 weeks shorter (p = 0.02) in those
who initially underwent amputation compared to those
who initially underwent internal resection, indicating
that internal resection may not be sufficient to eliminate
the infected tissue.
Fig. 4 The duration of immobilization in Group 1 with osteomyelitis outside the Charcot region (mean 83.1 ± 70.5, range 19 to 304 days) and in
Group 2 with osteomyelitis inside the Charcot region (mean 144 ± 91.8, range 17 to 389 days, p = 0.01) differed significantly (p = 0.01). The duration of
immobilization was similar for the different initial surgical treatments within each group. Asterisk = significant difference
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Four studies recently evaluated limb salvage proce-
dures as alternatives to amputation in Charcot foot and
ankle osteomyelitis. Farber et al. [38] reported that none
of the 11 patients with midfoot CN and ulceration who
underwent operative debridement and corrective osteot-
omy as a limb salvage procedure needed an amputation.
Dalla Paola et al. [39] reported four (9%) major amputa-
tions for failed infection control in 43 patients who
underwent arthrodesis [40] and external fixation as a
limb salvage procedure for CN and ankle osteomyelitis.
Pinzur et al. [41] reported 3 amputations (4.2%) in a co-
hort of 71 patients who underwent single-stage resection
of infection and correction of deformity with a ring fixa-
teur. Ramanujam et al. [42] reported one lower extrem-
ity amputation (3.7%) in 27 patients with diabetic CN
and osteomyelitis who underwent surgical reconstruc-
tion using circular external fixation.
A long-standing history (>10 years) of diabetes at the
time of initial diagnosis of CN is common [43, 44]. The
mean duration of treatment for diabetes in our study
was 15 (range: 0.6 to 53) years. No patient with insulin-
dependent diabetes received the diagnosis of diabetes
less than one year before the diagnosis of CN. However,
two patients with non–insulin-dependent diabetes had
an almost synchronous diagnosis of CN and diabetes,
suggesting that the initial occurrence of Charcot may
have guided the diagnosis of diabetes. There were less
patients (62%) with insulin-dependent diabetes com-
pared to the 75% previously reported in another study of
CN [45]. However, insulin dependency did not appear to
influence the amputation rate or amputation level.
In previous studies, noncompliance with treatment of
CN was determined to be the strongest predictor for re-
currence of CN, with an odds ratio of 19.7 [46, 47].
While the rate of noncompliance as recorded in patient
charts was high in the present study (38%), noncompli-
ance with treatment of the osteomyelitis did not appear
to influence the amputation rate or level of amputation.
The large number of patients excluded from this study
due to incomplete patient charts may have resulted in
selection bias. Typically, CN patients do not come in for
follow-up visits because they are poorly compliant with
treatment (i.e., total contact cast) or they do not under-
stand that they have a disease. The less complex cases
are often followed for longer durations than the severe
cases, to monitor their feet and their special shoes. Thus,
to minimize the potential selection bias for more severe
cases, we evaluated the effect of compliance with treat-
ment on amputation rate and amputation level.
Limitations of this study include the retrospective
study design, such that some pertinent factors that could
potentially affect treatment outcomes may not have been
recorded, and data collection at a single site, which
limits the generalizability of the conclusions. Another
limitation is the lack of recorded reasons for the initial
surgical treatment that was elected. Finally, the hetero-
geneity of initial surgical treatments performed in Group
2 patients and the relatively small sample sizes did not
allow further subgroup analysis.
Strengths of this study include the relatively large
sample size compared to other studies of CN, and the
detailed information available about the treatment regi-
mens. However, the heterogeneity of patients with this
disease and initial surgical treatment options limited
may require prospective trials with larger samples to
better elucidate the best treatment option for osteo-
myelitis in the presence of CN.
Conclusions
Patients treated for osteomyelitis within the Charcot
region on the foot underwent more high level amputations
and had longer durations of antibiotic treatment and
immobilization than patients treated for osteomyelitis out-
side the Charcot region, although the amputation rate was
similar for both groups. We recommend that. osteomyelitis
outside and within the Charcot affected region should be
regarded as separate entities when considering treatment
protocols and in future research evaluating the outcome
and treatment of CN and osteomyelitis. If osteomyelitis oc-
curs outside the active Charcot region, primary amputation
may be preferred to internal resection.
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